European School of Haematology (ESH)’s Post

You can see the Progress in treating relapsed Large B Cells with T-CAR cells by reading these two articles: OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT https://lnkd.in/dECECzVr CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA https://lnkd.in/dPSciJi5

Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial 

I am happy to announce this important success of our team: A 59-year-old woman with chemo-resistant relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) experienced a remarkable clinical response with a treatment combining CIK cells and a CD20 antigen-retargeting monoclonal antibody. This outcome underscores the potential of CIK cell-based strategies as a promising and viable alternative for patients who relapse, are refractory, or are ineligible for standard therapies, even after failing CAR T-cell therapy. The potential for broad applicability and the favorable safety profile introduces a new treatment paradigm for patients with CD20-positive non-Hodgkin lymphoma.  #CIKtherapy #adoptivecelltherapy #BcellLymphoma

Dear Colleagues, A recent publication in the American Journal of Case Reports by the authors from Temple University Hospital, Philadelphia, Pennsylvania, USA, presents a rare case of non-IgM lymphoplasmacytic lymphoma (LPL). This rare subtype, constituting less than 5% of cases, poses diagnostic challenges due to its similarity to other B-cell lymphomas. The case report describes a 67-year-old woman with weight loss, anemia, and leukopenia, whose bone marrow biopsy revealed abnormal B cells lacking light chain expression but producing intracytoplasmic IgA. Neoplastic plasma cells also showed no definitive light chain expression. This case expands our understanding of non-IgM LPL, shedding light on its diagnostic nuances. The complete report is now available on the American Journal of Case Reports webpage. #MedicalResearch #Lymphoma #CaseReport | https://lnkd.in/dZWXrAgT

Dear Colleagues, A recent publication in the American Journal of Case Reports by the authors from Temple University Hospital, Philadelphia, Pennsylvania, USA, presents a rare case of non-IgM lymphoplasmacytic lymphoma (LPL). This rare subtype, constituting less than 5% of cases, poses diagnostic challenges due to its similarity to other B-cell lymphomas. The case report describes a 67-year-old woman with weight loss, anemia, and leukopenia, whose bone marrow biopsy revealed abnormal B cells lacking light chain expression but producing intracytoplasmic IgA. Neoplastic plasma cells also showed no definitive light chain expression. This case expands our understanding of non-IgM LPL, shedding light on its diagnostic nuances. The complete report is now available on the American Journal of Case Reports webpage. #MedicalResearch #Lymphoma #CaseReport | https://lnkd.in/deKWzDPS

⭐ Phase II BrUOG-401 study ⭐ Treatment with fixed-duration subcutaneous mosunetuzumab demonstrated a high CR rate with limited toxicity in follicular lymphoma and marginal zone lymphoma. Read more from the study presented at #ASH24 by Matthew Matasar, MD, of Rutgers Robert Wood Johnson Medical School. ➡️ https://buff.ly/4g7IiFG

🧪 Fenbendazole: Mixed Results Against Lymphoma In vitro, FBZ halts cell division and induces death in EL-4 lymphoma cells. However, it shows no tumor-slowing effects in vivo, suggesting complex immune microenvironment interactions. ⚖️🦠 Read more :https://lnkd.in/dECRw_DT

Dr. Martin Dreyling presents results from the phase 3 ECHO trial at ASH 2024, evaluating the combination of acalabrutinib with bendamustine and rituximab in treating mantle cell lymphoma. This study demonstrated a significant improvement in PFS with a hazard ratio of 0.7 and a 10-15% increase in PFS rates. Although OS benefits were less clear due to the impact of the COVID-19 pandemic, the findings confirm that acalabrutinib improves outcomes, particularly for high-risk patients. 🔗 Read more about ASH 2024 here: https://lnkd.in/dMtDcqhe  #ASH24 #Lymphoma #Treatment

🔬 FDA has approved Breyanzi®, a CAR-T therapy for treating adult patients with relapsed or refractory mantle cell lymphoma. This marks the fourth distinct subtype of non-Hodgkin lymphoma that Bristol Myers Squibb’s Breyanzi® can treat, making it the broadest CAR-T cell therapy available for B-cell malignancies. Responses were observed in 85.3% of patients with a one-time infusion while maintaining a consistent safety profile in clinical trials. This highlights the potential of Breyanzi® to offer long-lasting responses for patients with few treatment alternatives. With the rising number of CAR-T therapy approvals, it's vital that these treatments are accessible and affordable for everyone, ensuring widespread patient access to these life-changing therapies. Book a demo to learn how IRO® can help scale the production and delivery of advanced therapies ➡️ https://lnkd.in/eXEXEGZZ Read more: https://lnkd.in/eMq-Vp8j #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

Dr. Martin Dreyling presents results from the phase 3 ECHO trial at ASH 2024, evaluating the combination of acalabrutinib with bendamustine and rituximab in treating mantle cell lymphoma. This study demonstrated a significant improvement in PFS with a hazard ratio of 0.7 and a 10-15% increase in PFS rates. Although OS benefits were less clear due to the impact of the COVID-19 pandemic, the findings confirm that acalabrutinib improves outcomes, particularly for high-risk patients. 🔗 Read more about ASH 2024 here: https://lnkd.in/dV_KtyXJ #ASH24 #Lymphoma #Treatment